BidaskClub upgraded shares of GALAPAGOS NV/S (NASDAQ:GLPG) from a sell rating to a hold rating in a report published on Friday.

A number of other equities research analysts also recently weighed in on GLPG. Stifel Nicolaus dropped their price target on shares of GALAPAGOS NV/S from $120.00 to $109.00 and set a buy rating for the company in a research note on Friday, June 29th. Zacks Investment Research raised shares of GALAPAGOS NV/S from a hold rating to a buy rating and set a $109.00 price target for the company in a research note on Wednesday, June 27th. ValuEngine raised shares of GALAPAGOS NV/S from a hold rating to a buy rating in a research note on Monday, July 2nd. Royal Bank of Canada dropped their price target on shares of GALAPAGOS NV/S to $94.00 and set a sector perform rating for the company in a research note on Friday, June 29th. Finally, Morgan Stanley boosted their price target on shares of GALAPAGOS NV/S from $125.00 to $126.00 and gave the stock an overweight rating in a research note on Friday, July 13th. Five analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average price target of $114.57.

GLPG opened at $107.73 on Friday. GALAPAGOS NV/S has a fifty-two week low of $84.13 and a fifty-two week high of $122.28.

GALAPAGOS NV/S (NASDAQ:GLPG) last posted its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported ($0.50) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.91) by $0.41. The business had revenue of $59.27 million during the quarter, compared to the consensus estimate of $50.58 million. GALAPAGOS NV/S had a negative net margin of 70.80% and a negative return on equity of 13.26%. On average, equities research analysts forecast that GALAPAGOS NV/S will post -2.92 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Castleark Management LLC grew its holdings in GALAPAGOS NV/S by 47.2% during the second quarter. Castleark Management LLC now owns 9,870 shares of the biotechnology company’s stock valued at $910,000 after purchasing an additional 3,166 shares during the period. Putnam Investments LLC grew its holdings in GALAPAGOS NV/S by 8.5% during the second quarter. Putnam Investments LLC now owns 22,682 shares of the biotechnology company’s stock valued at $2,091,000 after purchasing an additional 1,770 shares during the period. Aquilo Capital Management LLC acquired a new position in GALAPAGOS NV/S during the second quarter valued at approximately $6,088,000. Macquarie Group Ltd. grew its holdings in GALAPAGOS NV/S by 13.5% during the second quarter. Macquarie Group Ltd. now owns 9,865 shares of the biotechnology company’s stock valued at $909,000 after purchasing an additional 1,170 shares during the period. Finally, Bank of America Corp DE grew its holdings in GALAPAGOS NV/S by 11.7% during the second quarter. Bank of America Corp DE now owns 9,758 shares of the biotechnology company’s stock valued at $899,000 after purchasing an additional 1,025 shares during the period. 14.58% of the stock is owned by institutional investors and hedge funds.

GALAPAGOS NV/S Company Profile

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

Read More: What is the balance sheet?

Analyst Recommendations for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.